GlassScriptPhysician profile
Brett Michael Dickinson
NPI 1942287735
$3,579.32
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,501 · 2020: $612 · 2021: $418 · 2022: $48.26.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $446.53 | 2021-2022 | |
| Allergan, INC. | $375.52 | 2019-2020 | |
| Pfizer INC. | $341.70 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.50 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $247.84 | 2019-2020 | |
| Novo Nordisk INC | $247.66 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $235.72 | 2019-2020 | |
| Lilly USA, LLC | $186.46 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $167.82 | 2019 | |
| Astellas Pharma US INC | $144.86 | 2019 | |
| Daiichi Sankyo INC. | $135.46 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.78 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $65.18 | 2019 | |
| Amarin Pharma, INC. | $62.83 | 2019-2020 | |
| Amgen INC. | $62.03 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $60.00 | 2020 | |
| Glaxosmithkline, LLC. | $48.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.55 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.64 | 2019 | |
| Aytu Biopharma, INC. | $34.31 | 2019 | |
| Indivior INC. | $32.92 | 2019 | |
| Medtronic USA, INC. | $27.26 | 2019 | |
| Apria Healthcare LLC | $19.98 | 2021 | |
| Antares Pharma, INC. | $16.61 | 2020 | |
| Sanofi Pasteur INC. | $15.50 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.40 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.29 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.03 | 2019 | |
| Boston Scientific Corporation | $14.58 | 2019 | |
| Gilead Sciences, INC. | $12.71 | 2020 | |
| Scilex Pharmaceuticals INC. | $12.65 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.24 | 2020 | |
| Neos Therapeutics, LP | $11.74 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.69 | 2020 | |
| Shire North American Group INC | $11.22 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Dickinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.